<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36366549</PMID><DateCompleted><Year>2022</Year><Month>11</Month><Day>14</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>30</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1999-4915</ISSN><JournalIssue CitedMedium="Internet"><Volume>14</Volume><Issue>11</Issue><PubDate><Year>2022</Year><Month>Nov</Month><Day>04</Day></PubDate></JournalIssue><Title>Viruses</Title><ISOAbbreviation>Viruses</ISOAbbreviation></Journal><ArticleTitle>A Short 5'triphosphate RNA nCoV-L Induces a Broad-Spectrum Antiviral Response by Activating RIG-I.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">2451</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/v14112451</ELocationID><Abstract><AbstractText>Small molecular nucleic acid drugs produce antiviral effects by activating pattern recognition receptors (PRRs). In this study, a small molecular nucleotide containing 5'triphosphoric acid (5'PPP) and possessing a double-stranded structure was designed and named nCoV-L. nCoV-L was found to specifically activate RIG-I, induce interferon responses, and inhibit duplication of four RNA viruses (Human enterovirus 71, Human poliovirus 1, Huma<i>n</i> coxsackievirus B5 and Influenza A virus) in cells. In vivo, nCoV-L quickly induced interferon responses and protected BALB/c suckling mice from a lethal dose of the enterovirus 71. Additionally, prophylactic administration of nCoV-L was found to reduce mouse death and relieve morbidity symptoms in a K18-hACE2 mouse lethal model of SARS-CoV-2. In summary, these findings indicate that nCoV-L activates RIG-I and quickly induces effective antiviral signals. Thus, it has potential as a broad-spectrum antiviral drug.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Ziyang</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Biological Products Co., Ltd., Shanghai 201403, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bian</LastName><ForeName>Lianlian</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>An</LastName><ForeName>Chaoqiang</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Beijing Minhai Biotechnology Co., Ltd., Beijing 102629, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cui</LastName><ForeName>Bopei</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mao</LastName><ForeName>Qunying</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wu</LastName><ForeName>Xing</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>He</LastName><ForeName>Qian</ForeName><Initials>Q</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bai</LastName><ForeName>Yu</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Jianyang</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Song</LastName><ForeName>Lifang</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Dong</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Jialu</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gao</LastName><ForeName>Fan</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Xiuling</ForeName><Initials>X</Initials><AffiliationInfo><Affiliation>Shanghai Institute of Biological Products Co., Ltd., Shanghai 201403, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liang</LastName><ForeName>Zhenglun</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Division of Hepatitis and Enterovirus Vaccines, NHC Key Laboratory of Research on Quality and Standardization of Biotech Products, NMPA Key Laboratory for Quality Research and Evaluation of Biological Products, Institute of Biological Products, National Institutes for Food and Drug Control, Beijing 102600, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>11</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Viruses</MedlineTA><NlmUniqueID>101509722</NlmUniqueID><ISSNLinking>1999-4915</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>NU43IAG5BC</RegistryNumber><NameOfSubstance UI="C005692">triphosphoric acid</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D053487">DEAD-box RNA Helicases</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D012367">RNA, Viral</NameOfSubstance></Chemical><Chemical><RegistryNumber>EC 3.6.4.13</RegistryNumber><NameOfSubstance UI="D000071457">DEAD Box Protein 58</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000998">Antiviral Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>9008-11-1</RegistryNumber><NameOfSubstance UI="D007372">Interferons</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D053487" MajorTopicYN="N">DEAD-box RNA Helicases</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012367" MajorTopicYN="N">RNA, Viral</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002460" MajorTopicYN="N">Cell Line</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000071457" MajorTopicYN="N">DEAD Box Protein 58</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000998" MajorTopicYN="N">Antiviral Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007372" MajorTopicYN="N">Interferons</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">RIG-I</Keyword><Keyword MajorTopicYN="N">RNA agonist</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antiviral</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2022</Year><Month>9</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>11</Month><Day>2</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>11</Month><Day>11</Day><Hour>1</Hour><Minute>56</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>11</Month><Day>12</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>11</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36366549</ArticleId><ArticleId IdType="pmc">PMC9694983</ArticleId><ArticleId IdType="doi">10.3390/v14112451</ArticleId><ArticleId IdType="pii">v14112451</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Kanneganti T.-D. Intracellular innate immune receptors: Life inside the cell. Immunol. Rev. 2020;297:5&#x2013;12. doi: 10.1111/imr.12912.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imr.12912</ArticleId><ArticleId IdType="pmc">PMC7592123</ArticleId><ArticleId IdType="pubmed">32856334</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbalat R., Ewald S.E., Mouchess M.L., Barton G.M. Nucleic acid recognition by the innate immune system. Annu. Rev. Immunol. 2011;29:185&#x2013;214. doi: 10.1146/annurev-immunol-031210-101340.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev-immunol-031210-101340</ArticleId><ArticleId IdType="pubmed">21219183</ArticleId></ArticleIdList></Reference><Reference><Citation>Beutler B., Eidenschenk C., Crozat K., Imler J.L., Takeuchi O., Hoffmann J.A., Akira S. Genetic analysis of resistance to viral infection. Nat. Rev. Immunol. 2007;7:753&#x2013;766. doi: 10.1038/nri2174.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2174</ArticleId><ArticleId IdType="pubmed">17893693</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlee M., Hartmann G. The chase for the RIG-I ligand--recent advances. Mol. Ther. 2010;18:1254&#x2013;1262. doi: 10.1038/mt.2010.90.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2010.90</ArticleId><ArticleId IdType="pmc">PMC2911265</ArticleId><ArticleId IdType="pubmed">20461060</ArticleId></ArticleIdList></Reference><Reference><Citation>Goubau D., Schlee M., Deddouche S., Pruijssers A.J., Zillinger T., Goldeck M., Schuberth C., Van der Veen A.G., Fujimura T., Rehwinkel J., et al. Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5&#x2032;-diphosphates. Nature. 2014;514:372&#x2013;375. doi: 10.1038/nature13590.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature13590</ArticleId><ArticleId IdType="pmc">PMC4201573</ArticleId><ArticleId IdType="pubmed">25119032</ArticleId></ArticleIdList></Reference><Reference><Citation>Okamoto M., Kouwaki T., Fukushima Y., Oshiumi H. Regulation of RIG-I Activation by K63-Linked Polyubiquitination. Front. Immunol. 2017;8:1942. doi: 10.3389/fimmu.2017.01942.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01942</ArticleId><ArticleId IdType="pmc">PMC5760545</ArticleId><ArticleId IdType="pubmed">29354136</ArticleId></ArticleIdList></Reference><Reference><Citation>Fujita T. A nonself RNA pattern: Tri-p to panhandle. Immunity. 2009;31:4&#x2013;5. doi: 10.1016/j.immuni.2009.06.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.06.014</ArticleId><ArticleId IdType="pubmed">19604485</ArticleId></ArticleIdList></Reference><Reference><Citation>Bamming D., Horvath C.M. Regulation of signal transduction by enzymatically inactive antiviral RNA helicase proteins MDA5, RIG-I, and LGP2. J. Biol. Chem. 2009;284:9700&#x2013;9712. doi: 10.1074/jbc.M807365200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M807365200</ArticleId><ArticleId IdType="pmc">PMC2665091</ArticleId><ArticleId IdType="pubmed">19211564</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Takahashi K., Sato S., Coban C., Kumar H., Kato H., Ishii K.J., Takeuchi O., Akira S. IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. Nat. Immunol. 2005;6:981&#x2013;988. doi: 10.1038/ni1243.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni1243</ArticleId><ArticleId IdType="pubmed">16127453</ArticleId></ArticleIdList></Reference><Reference><Citation>Seth R.B., Sun L., Ea C.K., Chen Z.J. Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell. 2005;122:669&#x2013;682. doi: 10.1016/j.cell.2005.08.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2005.08.012</ArticleId><ArticleId IdType="pubmed">16125763</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Takeuchi O., Akira S. Cell type specific involvement of RIG-I in antiviral responses. Nihon Rinsho. 2006;64:1244&#x2013;1247. doi: 10.1016/j.immuni.2005.04.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.04.010</ArticleId><ArticleId IdType="pubmed">16838639</ArticleId></ArticleIdList></Reference><Reference><Citation>Onomoto K., Onoguchi K., Yoneyama M. Regulation of RIG-I-like receptor-mediated signaling: Interaction between host and viral factors. Cell. Mol. Immunol. 2021;18:539&#x2013;555. doi: 10.1038/s41423-020-00602-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-00602-7</ArticleId><ArticleId IdType="pmc">PMC7812568</ArticleId><ArticleId IdType="pubmed">33462384</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonz&#xe1;lez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat. Rev. Immunol. 2012;12:125&#x2013;135. doi: 10.1038/nri3133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3133</ArticleId><ArticleId IdType="pmc">PMC3727154</ArticleId><ArticleId IdType="pubmed">22222875</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivashkiv L.B., Donlin L.T. Regulation of type I interferon responses. Nat. Rev. Immunol. 2014;14:36&#x2013;49. doi: 10.1038/nri3581.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3581</ArticleId><ArticleId IdType="pmc">PMC4084561</ArticleId><ArticleId IdType="pubmed">24362405</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin F.C., Young H.A. Interferons: Success in anti-viral immunotherapy. Cytokine Growth Factor Rev. 2014;25:369&#x2013;376. doi: 10.1016/j.cytogfr.2014.07.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2014.07.015</ArticleId><ArticleId IdType="pmc">PMC4182113</ArticleId><ArticleId IdType="pubmed">25156421</ArticleId></ArticleIdList></Reference><Reference><Citation>Goubau D., Deddouche S., Reis e Sousa C. Cytosolic sensing of viruses. Immunity. 2013;38:855&#x2013;869. doi: 10.1016/j.immuni.2013.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2013.05.007</ArticleId><ArticleId IdType="pmc">PMC7111113</ArticleId><ArticleId IdType="pubmed">23706667</ArticleId></ArticleIdList></Reference><Reference><Citation>Rathinam V.A., Fitzgerald K.A. Inflammasomes and anti-viral immunity. J. Clin. Immunol. 2010;30:632&#x2013;637. doi: 10.1007/s10875-010-9431-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10875-010-9431-4</ArticleId><ArticleId IdType="pubmed">20665097</ArticleId></ArticleIdList></Reference><Reference><Citation>Linehan M.M., Dickey T.H., Molinari E.S., Fitzgerald M.E., Potapova O., Iwasaki A., Pyle A.M. A minimal RNA ligand for potent RIG-I activation in living mice. Sci. Adv. 2018;4:e1701854. doi: 10.1126/sciadv.1701854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciadv.1701854</ArticleId><ArticleId IdType="pmc">PMC5821489</ArticleId><ArticleId IdType="pubmed">29492454</ArticleId></ArticleIdList></Reference><Reference><Citation>Bastard P., Rosen L.B., Zhang Q., Michailidis E., Hoffmann H.H., Zhang Y., Dorgham K., Philippot Q., Rosain J., B&#xe9;ziat V., et al. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. Science. 2020;370:eabd4585. doi: 10.1126/science.abd4585.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abd4585</ArticleId><ArticleId IdType="pmc">PMC7857397</ArticleId><ArticleId IdType="pubmed">32972996</ArticleId></ArticleIdList></Reference><Reference><Citation>Giovannoni G., Munschauer F.E., 3rd, Deisenhammer F. Neutralising antibodies to interferon beta during the treatment of multiple sclerosis. J. Neurol. Neurosurg. Psychiatry. 2002;73:465&#x2013;469. doi: 10.1136/jnnp.73.5.465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/jnnp.73.5.465</ArticleId><ArticleId IdType="pmc">PMC1738139</ArticleId><ArticleId IdType="pubmed">12397132</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsuda F., Torii Y., Enomoto H., Kuga C., Aizawa N., Iwata Y., Saito M., Imanishi H., Shimomura S., Nakamura H., et al. Anti-interferon-&#x3b1; neutralizing antibody is associated with nonresponse to pegylated interferon-&#x3b1; plus ribavirin in chronic hepatitis C. J. Viral Hepat. 2012;19:694&#x2013;703. doi: 10.1111/j.1365-2893.2012.01598.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2893.2012.01598.x</ArticleId><ArticleId IdType="pubmed">22967100</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiang C., Beljanski V., Yin K., Olagnier D., Ben Yebdri F., Steel C., Goulet M.L., DeFilippis V.R., Streblow D.N., Haddad E.K., et al. Sequence-Specific Modifications Enhance the Broad-Spectrum Antiviral Response Activated by RIG-I Agonists. J. Virol. 2015;89:8011&#x2013;8025. doi: 10.1128/JVI.00845-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.00845-15</ArticleId><ArticleId IdType="pmc">PMC4505665</ArticleId><ArticleId IdType="pubmed">26018150</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V., Ellegast J., Kim S., Brz&#xf3;zka K., Jung A., Kato H., Poeck H., Akira S., Conzelmann K.K., Schlee M., et al. 5&#x2032;-Triphosphate RNA is the ligand for RIG-I. Science. 2006;314:994&#x2013;997. doi: 10.1126/science.1132505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132505</ArticleId><ArticleId IdType="pubmed">17038590</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Takeuchi O., Sato S., Yoneyama M., Yamamoto M., Matsui K., Uematsu S., Jung A., Kawai T., Ishii K.J., et al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature. 2006;441:101&#x2013;105. doi: 10.1038/nature04734.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature04734</ArticleId><ArticleId IdType="pubmed">16625202</ArticleId></ArticleIdList></Reference><Reference><Citation>Pichlmair A., Schulz O., Tan C.P., N&#xe4;slund T.I., Liljestr&#xf6;m P., Weber F., Reis e Sousa C. RIG-I-mediated antiviral responses to single-stranded RNA bearing 5&#x2032;-phosphates. Science. 2006;314:997&#x2013;1001. doi: 10.1126/science.1132998.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1132998</ArticleId><ArticleId IdType="pubmed">17038589</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang M., Zhang S., Yang Z., Lin H., Zhu J., Liu L., Wang W., Liu S., Liu W., Ma Y., et al. Self-Recognition of an Inducible Host lncRNA by RIG-I Feedback Restricts Innate Immune Response. Cell. 2018;173:906&#x2013;919.e913. doi: 10.1016/j.cell.2018.03.064.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2018.03.064</ArticleId><ArticleId IdType="pubmed">29706547</ArticleId></ArticleIdList></Reference><Reference><Citation>Brisse M., Ly H. Comparative Structure and Function Analysis of the RIG-I-Like Receptors: RIG-I and MDA5. Front. Immunol. 2019;10:1586. doi: 10.3389/fimmu.2019.01586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01586</ArticleId><ArticleId IdType="pmc">PMC6652118</ArticleId><ArticleId IdType="pubmed">31379819</ArticleId></ArticleIdList></Reference><Reference><Citation>McCray P.B., Jr., Pewe L., Wohlford-Lenane C., Hickey M., Manzel L., Shi L., Netland J., Jia H.P., Halabi C., Sigmund C.D., et al. Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus. J. Virol. 2007;81:813&#x2013;821. doi: 10.1128/JVI.02012-06.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.02012-06</ArticleId><ArticleId IdType="pmc">PMC1797474</ArticleId><ArticleId IdType="pubmed">17079315</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng J., Wong L.R., Li K., Verma A.K., Ortiz M.E., Wohlford-Lenane C., Leidinger M.R., Knudson C.M., Meyerholz D.K., McCray P.B., Jr., et al. COVID-19 treatments and pathogenesis including anosmia in K18-hACE2 mice. Nature. 2021;589:603&#x2013;607. doi: 10.1038/s41586-020-2943-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2943-z</ArticleId><ArticleId IdType="pmc">PMC7855185</ArticleId><ArticleId IdType="pubmed">33166988</ArticleId></ArticleIdList></Reference><Reference><Citation>Winkler E.S., Bailey A.L., Kafai N.M., Nair S., McCune B.T., Yu J., Fox J.M., Chen R.E., Earnest J.T., Keeler S.P., et al. SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function. Nat. Immunol. 2020;21:1327&#x2013;1335. doi: 10.1038/s41590-020-0778-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-020-0778-2</ArticleId><ArticleId IdType="pmc">PMC7578095</ArticleId><ArticleId IdType="pubmed">32839612</ArticleId></ArticleIdList></Reference><Reference><Citation>Schlee M., Roth A., Hornung V., Hagmann C.A., Wimmenauer V., Barchet W., Coch C., Janke M., Mihailovic A., Wardle G., et al. Recognition of 5&#x2032; triphosphate by RIG-I helicase requires short blunt double-stranded RNA as contained in panhandle of negative-strand virus. Immunity. 2009;31:25&#x2013;34. doi: 10.1016/j.immuni.2009.05.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2009.05.008</ArticleId><ArticleId IdType="pmc">PMC2824854</ArticleId><ArticleId IdType="pubmed">19576794</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng Q., Langereis M.A., Olagnier D., Chiang C., van de Winkel R., van Essen P., Zoll J., Hiscott J., van Kuppeveld F.J. Coxsackievirus cloverleaf RNA containing a 5&#x2032; triphosphate triggers an antiviral response via RIG-I activation. PLoS ONE. 2014;9:e95927. doi: 10.1371/journal.pone.0095927.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0095927</ArticleId><ArticleId IdType="pmc">PMC3997492</ArticleId><ArticleId IdType="pubmed">24759703</ArticleId></ArticleIdList></Reference><Reference><Citation>Goulet M.L., Olagnier D., Xu Z., Paz S., Belgnaoui S.M., Lafferty E.I., Janelle V., Arguello M., Paquet M., Ghneim K., et al. Systems analysis of a RIG-I agonist inducing broad spectrum inhibition of virus infectivity. PLoS Pathog. 2013;9:e1003298. doi: 10.1371/annotation/8fa70b21-32e7-4ed3-b397-ab776b5bbf30.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/annotation/8fa70b21-32e7-4ed3-b397-ab776b5bbf30</ArticleId><ArticleId IdType="pmc">PMC3635991</ArticleId><ArticleId IdType="pubmed">23633948</ArticleId></ArticleIdList></Reference><Reference><Citation>Jia J., Fu J., Tang H. Activation and Evasion of RLR Signaling by DNA Virus Infection. Front. Microbiol. 2021;12:804511. doi: 10.3389/fmicb.2021.804511.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2021.804511</ArticleId><ArticleId IdType="pmc">PMC8721196</ArticleId><ArticleId IdType="pubmed">34987495</ArticleId></ArticleIdList></Reference><Reference><Citation>Konno Y., Kimura I., Uriu K., Fukushi M., Irie T., Koyanagi Y., Sauter D., Gifford R.J., Nakagawa S., Sato K. SARS-CoV-2 ORF3b Is a Potent Interferon Antagonist Whose Activity Is Increased by a Naturally Occurring Elongation Variant. Cell Rep. 2020;32:108185. doi: 10.1016/j.celrep.2020.108185.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2020.108185</ArticleId><ArticleId IdType="pmc">PMC7473339</ArticleId><ArticleId IdType="pubmed">32941788</ArticleId></ArticleIdList></Reference><Reference><Citation>Setaro A.C., Gaglia M.M. All hands on deck: SARS-CoV-2 proteins that block early anti-viral interferon responses. Curr. Res. Virol. Sci. 2021;2:100015. doi: 10.1016/j.crviro.2021.100015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crviro.2021.100015</ArticleId><ArticleId IdType="pmc">PMC8588586</ArticleId><ArticleId IdType="pubmed">34786565</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu X., Pan J., Tao J., Guo D. SARS-CoV nucleocapsid protein antagonizes IFN-&#x3b2; response by targeting initial step of IFN-&#x3b2; induction pathway, and its C-terminal region is critical for the antagonism. Virus Genes. 2011;42:37&#x2013;45. doi: 10.1007/s11262-010-0544-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11262-010-0544-x</ArticleId><ArticleId IdType="pmc">PMC7088804</ArticleId><ArticleId IdType="pubmed">20976535</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamada T., Sato S., Sotoyama Y., Orba Y., Sawa H., Yamauchi H., Sasaki M., Takaoka A. RIG-I triggers a signaling-abortive anti-SARS-CoV-2 defense in human lung cells. Nat. Immunol. 2021;22:820&#x2013;828. doi: 10.1038/s41590-021-00942-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00942-0</ArticleId><ArticleId IdType="pubmed">33976430</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu D., Biswal M., Neal A., Hai R. Review Devil&#x2019;s tools: SARS-CoV-2 antagonists against innate immunity. Curr. Res. Virol. Sci. 2021;2:100013. doi: 10.1016/j.crviro.2021.100013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.crviro.2021.100013</ArticleId><ArticleId IdType="pmc">PMC8598260</ArticleId><ArticleId IdType="pubmed">34812428</ArticleId></ArticleIdList></Reference><Reference><Citation>Bojkova D., Widera M., Ciesek S., Wass M.N., Michaelis M., Cinatl J., Jr. Reduced interferon antagonism but similar drug sensitivity in Omicron variant compared to Delta variant of SARS-CoV-2 isolates. Cell Res. 2022;32:319&#x2013;321. doi: 10.1038/s41422-022-00619-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-022-00619-9</ArticleId><ArticleId IdType="pmc">PMC8781709</ArticleId><ArticleId IdType="pubmed">35064226</ArticleId></ArticleIdList></Reference><Reference><Citation>Mao T., Israelow B., Lucas C., Vogels C.B.F., Gomez-Calvo M.L., Fedorova O., Breban M.I., Menasche B.L., Dong H., Linehan M., et al. A stem-loop RNA RIG-I agonist protects against acute and chronic SARS-CoV-2 infection in mice. J. Exp. Med. 2022;219:e20211818. doi: 10.1084/jem.20211818.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20211818</ArticleId><ArticleId IdType="pmc">PMC8590200</ArticleId><ArticleId IdType="pubmed">34757384</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>